Skip to content

Released Aug 13, 2024, after the close

10-Q filed Aug 13, 2024, 44 days after period end · 0000950170-24-096336

Q2 2024 · 10-Q
Revenue$25.71M+146.9% vs Q2 2023+97.6% vs Q1 2024
Net Income-$48.02MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.59N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$48,685,000N/M
Operating Cash Flowderived$9,455,000N/M
Margins · derived
Operating margin-189.4%+254.1 pt vs Q2 2023
Net margin-186.8%+183.2 pt vs Q2 2023

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$25.71M$10.41M$28.10M$28.05M
Net Income-$48.02M-$38.52M-$26.01M-$6.15M
EPS Diluted-$0.59-$0.64-$0.55-$0.13

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR